Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has

In a quiet corner of east London, where the City skyline looms large through the windows, there’s a place where machines hum like washer-dryers, spotless surfaces are cleaned on a

Dublin-listed Open Orphan is currently developing the world’s first challenge study model to test the effectiveness of Covid-19 vaccines that are in development. These types of studies have the potential

Dublin-listed pharmaceutical services company Open Orphan said it has developed the world’s first challenge study model to test the efficacy of the large number of potential Covid-19 vaccines. Challenge study models involve

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study model, has announce

Five years ago, in an office complex with a giant sculpture of a mosquito just northwest of Phnom Penh, Jessica Manning struck on a novel idea. Rather than spend more

Looking beyond the search for a malaria vaccine, one team of researchers is testing whether a vaccine made of mosquito spit proteins can invoke an immune response, which could in turn protect

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, has announced